GLTO
- Galecto, Inc.
()
Overview
Company Summary
Galecto, Inc. is a biotechnology company focused on developing innovative therapies for fibrotic diseases and cancer. Galecto specifically targets diseases that involve excessive tissue scarring, targeting a class of proteins called galectins. These proteins play a crucial role in promoting inflammation and fibrosis, which can lead to tissue damage and organ dysfunction.
Galecto's primary approach involves developing small molecule inhibitors that selectively bind to galectins, blocking their activity and reducing inflammation and fibrosis. By targeting galectins, Galecto aims to halt the progression of fibrotic diseases and potentially reverse the damage caused in affected organs.
The company's pipeline includes potential treatments for various fibrotic diseases, including idiopathic pulmonary fibrosis, liver fibrosis, and myelofibrosis. Galecto's lead drug candidate, GB0139, has shown promising results in clinical trials for idiopathic pulmonary fibrosis, a serious and life-threatening lung disease.
In addition to fibrotic diseases, Galecto is also exploring the application of galectin inhibitors in cancer treatment. By targeting galectins, the company aims to disrupt the tumor microenvironment, potentially enhancing the effectiveness of other cancer therapies and helping to control tumor growth and metastasis.
Overall, Galecto, Inc. is dedicated to developing novel therapies utilizing galectin inhibitors to address fibrotic diseases and potentially improve treatment outcomes for cancer patients.